Evolus (EOLS) Gains from Investment Securities (2018 - 2026)
Evolus (EOLS) posted Gains from Investment Securities of -$14000.0 for Q1 2026, up 99.69% on a QoQ basis from -$4.5 million in Q4 2025, and down 100.65% year-over-year from $2.2 million in Q1 2025.
Evolus (EOLS) Gains from Investment Securities (2018 - 2026) Analysis & Trends
Evolus' Gains from Investment Securities history runs 9 years deep, the most recent figure standing at -$14000.0 for Q1 2026.
- Quarterly Gains from Investment Securities fell 100.65% year-over-year to -$14000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.5 million (down 210.29% YoY) and the FY2025 annual result came in at -$6.4 million, down 188.92% from the prior year.
- Gains from Investment Securities was -$14000.0 for Q1 2026 at Evolus, up from -$4.5 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $2.4 million in Q3 2024 and bottomed at -$4.5 million in Q4 2025.
- A 5-year average of $634882.4 and a median of $1.6 million in 2024 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2024 — Gains from Investment Securities surged 278.86% — and 2025, when it sank 388.24%.
- Evolus' Gains from Investment Securities stood at $1.8 million in 2022, then sank by 148.37% to -$875000.0 in 2023, then jumped by 278.86% to $1.6 million in 2024, then sank by 388.24% to -$4.5 million in 2025, then surged by 99.69% to -$14000.0 in 2026.
- Business Quant data shows EOLS's Gains from Investment Securities at -$14000.0 in Q1 2026, -$4.5 million in Q4 2025, and -$107000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Evolus | 403.51 Mn | 353.71 Mn | 48.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,000.00 |
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | -4.51 Mn |
| Dec 31, 2025 | -4.51 Mn |
| Sep 30, 2025 | -107,000.00 |
| Sep 30, 2025 | -107,000.00 |
| Jun 30, 2025 | -3.91 Mn |
| Jun 30, 2025 | -3.91 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Mar 31, 2025 | 2.15 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Dec 31, 2024 | 1.57 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | -875,000.00 |
| Dec 31, 2023 | -875,000.00 |